

National Institute of Pharmacy and Nutrition

CERTIFICATE NUMBER: *OGYÉI/52010-11/2018*

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER^{1, 2}

Part 1

Issued following an inspection in accordance with :

Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Hungary confirms the following:

The manufacturer: *Steril-Gene Life Sciences (P) Limited*

Site address: *No. 45, Mangalam Main Road, Villianur Commune, Puducherry, 605 110, India*

Has been inspected in connection with marketing authorisation(s) listing manufacturers located outside of the European Economic Area in accordance with Art. 111(4) of Directive 2001/83/EC .

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2019-08-16** , it is considered that it complies with :

- The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC³

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

¹ The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

² Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

³ These requirements fulfil the GMP recommendations of WHO.

Part 2


Human Medicinal Products	
1 MANUFACTURING OPERATIONS	
1.2	Non-sterile products
	<i>1.2.1 Non-sterile products (processing operations for the following dosage forms)</i> 1.2.1.2 Capsules, soft shell 1.2.1.13 Tablets
1.5	Packaging
	<i>1.5.1 Primary Packing</i> 1.5.1.2 Capsules, soft shell 1.5.1.13 Tablets
	<i>1.5.2 Secondary packing</i>
1.6	Quality control testing
	1.6.2 Microbiological: non-sterility 1.6.3 Chemical/Physical

Clarifying remarks (for public users)

The inspection covered Block B, hormone manufacturing, and Block D, general oral solid dosage manufacturing.

2020-01-03

Name and signature of the authorised person of the
Competent Authority of Hungary



Dr. Lukacs Ferenc
National Institute of Pharmacy and Nutrition
Tel:
Fax:

